German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Antiprotozoal-antibacterials. |
| Generic Name : | Tinidazole - Genital infections |
| Drug description : | White f-c tablets embossed on one side with FAS 500. |
| Presentation : | Tablets, tinidazole 500 mg . |
| Indications : | Bacterial vaginosis, urogenital trichomoniasis. |
| Adult Dosage : | Single dose of 4 tablets. |
| Child Dosage : | 50 - 75 mg/kg as a single dose. Repeat once if necessary. Repeat once if necessary. |
| Contra Indications : | Blood dyscrasias, organic neurological disorders. 1st trimester of pregnancy, lactation. Hypersensitivity. |
| Special Precautions : | 2nd and 3rd trimester of pregnancy. Lactation - for three days after discontinuation of Fasigyn. |
| Interactions : | Alcohol. |
| Adverse Reactions : | GI distress, furred tongue, unpleasant taste. Urticaria, angioedema, CNS disturbances, dark urine. Neuropathy and transient leucopenia on long term therapy. Headache. Hypersensitivity reactions: rash, urticaria, pruritus, angio- neurotic oedema. |
| Manufacturer : | Pfizer |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org

Medical News


![The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC] The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]](/images/banners/nsclc.gif)